Nanexa AB (DE:40M)
FRANKFURT:40M
40M Stock Chart & Stats
€0.25
>-€0.01(-2.14%)
At close: 4:00 PM EST
€0.25
>-€0.01(-2.14%)
Day’s Range― - ―
52-Week Range€0.07 - €0.43
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€57.05M
Enterprise Value€617.20M
Total Cash (Recent Filing)€44.57M
Total Debt (Recent Filing)€1.12M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding164,585,050
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)6.83
Price to Sales (P/S)19.19
P/FCF Ratio-26.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€10.36M
Bulls Say, Bears Say
Bulls Say
Partnering / Licensing Business ModelNanexa’s licensing-focused model leverages partner commercialization to scale revenue with low incremental capital needs. Upfront, milestone and royalty streams create multiple future cash levers and align partner incentives, reducing Nanexa’s need to build a large sales organization and preserving capital over the medium term.
Platform Technology (PharmaShell)A platform that enables long-acting injectables across multiple drug substances provides structural competitive advantage. Platform reuse across programs spreads R&D costs, increases optionality for out-licensing, and creates higher switching costs for partners seeking established LAI formulation expertise.
Low Financial LeverageConservative leverage and sizeable equity provide financing flexibility and lower insolvency risk while the company funds development. Low debt reduces interest burden and preserves capacity for strategic partnerships or opportunistic financing during the next 2–6 months as product programs advance.
Bears Say
Persistent Cash Burn / Negative FCFDespite improvement, sustained negative free cash flow indicates ongoing external funding needs. Continued cash burn raises execution and dilution risk over the medium term, potentially forcing financing decisions that could constrain strategic flexibility or slow program timelines if partners do not accelerate payments.
Profitability Not Yet SustainableWhile losses have narrowed and EBITDA turned positive, negative operating and net margins show the business hasn’t reached durable profitability. The company remains sensitive to cost structure and scale economics; translating revenue growth into sustained profits is required to remove ongoing funding dependence.
Very Small Internal TeamA lean headcount limits internal development, regulatory and partnership management capacity. This increases reliance on external partners and CROs and creates execution risk when advancing multiple programs or negotiating complex licensing deals, potentially slowing timelines or diluting oversight.
Nanexa AB News
40M FAQ
What was Nanexa AB’s price range in the past 12 months?
Nanexa AB lowest stock price was €0.07 and its highest was €0.43 in the past 12 months.
What is Nanexa AB’s market cap?
Nanexa AB’s market cap is €57.05M.
When is Nanexa AB’s upcoming earnings report date?
Nanexa AB’s upcoming earnings report date is Apr 29, 2026 which is in 27 days.
How were Nanexa AB’s earnings last quarter?
Nanexa AB released its earnings results on Feb 19, 2026. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of N/A by €0.009.
Is Nanexa AB overvalued?
According to Wall Street analysts Nanexa AB’s price is currently Overvalued.
Does Nanexa AB pay dividends?
Nanexa AB does not currently pay dividends.
What is Nanexa AB’s EPS estimate?
Nanexa AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanexa AB have?
Nanexa AB has 164,585,050 shares outstanding.
What happened to Nanexa AB’s price movement after its last earnings report?
Nanexa AB reported an EPS of €0.009 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.968%.
Which hedge fund is a major shareholder of Nanexa AB?
Currently, no hedge funds are holding shares in DE:40M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanexa AB
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
Vivesto AB
―
Klaria Pharma Holding AB
―
Enzymatica AB
―
Enorama Pharma AB
―